LivaNova PLC (NASDAQ:LIVN) Receives $69.17 Average Price Target from Brokerages

LivaNova PLC (NASDAQ:LIVN) has been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $69.17.

LIVN has been the subject of several analyst reports. Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of LivaNova in a research note on Monday, November 25th. The Goldman Sachs Group began coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target for the company. Finally, Robert W. Baird lifted their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st.

Insider Activity

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Hedge funds have recently made changes to their positions in the company. KBC Group NV increased its holdings in LivaNova by 130.5% in the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock valued at $4,628,000 after buying an additional 56,580 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of LivaNova in the fourth quarter worth approximately $1,954,000. Diversified Trust Co boosted its stake in LivaNova by 9.5% during the 4th quarter. Diversified Trust Co now owns 16,432 shares of the company’s stock worth $761,000 after purchasing an additional 1,425 shares during the last quarter. Nordea Investment Management AB grew its stake in LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after acquiring an additional 12,470 shares in the last quarter. Finally, Central Pacific Bank Trust Division boosted its holdings in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Performance

NASDAQ LIVN opened at $48.15 on Wednesday. The firm has a market cap of $2.61 billion, a P/E ratio of 114.64 and a beta of 1.01. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company’s 50 day moving average is $49.19 and its 200-day moving average is $50.02. LivaNova has a 12-month low of $43.15 and a 12-month high of $64.47.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.